Rationalization of Genetic Testing in Patients with Apparently Sporadic Pheochromocytoma/Paraganglioma
Alberto Cascón(Spanish National Cancer Research Centre), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Elena López‐Jiménez(Spanish National Cancer Research Centre), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Carlos Fernando Sanabria, Iñigo Landa(Inserm), Susanna Leskelä(Spanish National Cancer Research Centre), Leticia de la Vega, Agnieszka Maliszewska(Spanish National Cancer Research Centre), Rocío Letón, María García‐Barcina(Hospital de Basurto), Luis J. Leandro‐García(Spanish National Cancer Research Centre)
Cited by 44
Related Papers
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394
<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
|Clinical Cancer Research|2012|330
An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes
|Hormone and Metabolic Research|2012|287